| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Omeros Corporation$8.67
-2.08 (-19.4%)
C 47Pipeline Score Fair Value Pharma · Commercial
Market Cap
829.42 M
EPS
1.10
P/E Ratio
13.39 $
Value Trade
18.66 M
SEC Financials
Q1 2026Dilution Risk
Revenue
9.89 M
R&D Expenses
13.36 M
Operating CF
-14.51 M
Total Assets
286.17 M
Total Liabilities
286.17 M
Equity
-63.33 M
D/E Ratio
12,345
-10.89 %
Week
-15.24 %
1 Month
-3.37 %
3 Month
42.36 %
6 Month
-24.9 %
5 Year
30.23 %
All Time
Cash Data
Cash Position
135.32 M
Monthly Burn
4.83 M
Runway
26.6 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
10.92 M
52 Week Range
2.95 - 17.65
% held by Insiders
3.56 %
% held by Institutions
43.9 %
Enterprise Value
1.00 B
Total Shares
70.91 M
Short %
29.76 %
Float Shares
60.84 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
C47
Pipeline Score $893M
Pipeline ValueFair Value
Valuation Signal8
Drugs Scored1.1x
rNPV / MCap Top 72%
Micro Cap (rank 254 of 905)
Percentile RankOmeros Corporation carries a moderate pipeline score (47/100), with $2.2B risk-adjusted pipeline value, led by OMS103HP in Postoperative Pain (Phase 2), across $80B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OMS103HP Small molecule | Knee Injuries | Phase 3 | NCT00226759 | 50% | $1.2B | COMPLETED | 647 | - | - | Mar 1, 2011 | - | Oct 12, 2012 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
narsoplimab | hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) | Phase 3 | 2025-08-15 | |||
narsoplimab | hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) | Phase 3 | 2025-08-15 | |||
narsoplimab | hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) | Phase 3 | 2025-08-15 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in OMER
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
OMER
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
OMER
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
OMER
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
OMER Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
OMER Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
OMEROmeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMA
Omeros Corporation has provided an update regarding its European Marketing Authorization Application for narsoplimab, a treatment for TA-TMA. The details of the update have not been disclosed in the article. The company continues to pursue regulatory approval in Europe for this indication.
Read more →OMEROmeros Announces Webcast Details for Annual Meeting of Shareholders
Omeros has announced the details for its upcoming Annual Meeting of Shareholders. The webcast will provide shareholders with insights into the company's performance and future strategies. Further specifics about the meeting's agenda and participation were not disclosed in the announcement.
Read more →OMEROmeros Corporation Reports First Quarter 2026 Financial Results
Omeros Corporation has reported its financial results for the first quarter of 2026. The article provides insights into the company's performance but lacks detailed information on specific financial metrics or operational updates. Overall, the report appears to be a standard financial disclosure without significant developments.
Read more →OMEROmeros Corporation to Announce First Quarter Financial Results on May 13, 2026
Omeros Corporation is set to announce its financial results for the first quarter on May 13, 2026. This announcement is part of the company's regular financial reporting schedule. Further details regarding the results will likely be provided during the announcement.
Read more →OMERCMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)
Omeros Corporation announced that CMS has assigned a permanent J-code for YARTEMLEA, enhancing billing and reimbursement processes for patients. Effective July 1, 2026, this J-code will facilitate access to treatment for TA-TMA, a severe complication of hematopoietic stem cell transplantation. The initiative aims to reduce administrative burdens and improve patient care.
Read more →OMEROmeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results
Omeros Corporation reported strong financial results for Q4 and the year ending December 31, 2025, highlighted by the FDA approval of YARTEMLEA and a successful commercial launch. The company recognized significant net income and reduced its debt substantially. A partnership with Novo Nordisk is expected to enhance its pipeline and financial stability, despite a net loss for the year.
Read more →OMEROmeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026
Omeros Corporation announced it will release its financial results for Q4 and the full year of 2025 on March 31, 2026. A conference call will follow to discuss the results and recent developments. The company is known for its innovative therapeutics, including the FDA-approved YARTEMLEA for TA-TMA. Omeros is also advancing its pipeline with various clinical programs.
Read more →OMEROmeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment
Omeros Corporation announced its participation in the upcoming EBMT 2026 meeting, where it will host a session on advances in TA-TMA treatment. The session will be co-chaired by notable experts and feature discussions on novel targeted therapies. Omeros continues to develop innovative treatments, including its FDA-approved product YARTEMLEA for TA-TMA.
Read more →OMEROmeros Announces Successful Primate Study in OncotoX-AML™ Drug Program
Omeros Corporation announced the successful completion of a primate study for its OncotoX-AML cancer therapeutic, targeting acute myeloid leukemia (AML). The study showed a significant reduction in myeloid progenitor cells and no adverse safety signals. Omeros plans to initiate IND-enabling studies to advance OncotoX-AML to clinical trials, aiming for a first-in-human trial by late 2027.
Read more →OMEROmeros Announces First Commercial Sales of YARTEMLEA®
Omeros Corporation has announced the first commercial sales of YARTEMLEA, the only approved treatment for stem cell transplant-associated thrombotic microangiopathy (TA-TMA). The drug is now being administered to both adult and pediatric patients, including those who previously failed other treatments. YARTEMLEA selectively inhibits MASP-2, a key enzyme in the complement pathway, and has received FDA approval. A marketing authorization application for the drug is also under review by the European Medicines Agency.
Read more →OMEROmeros Announces New Date for YARTEMLEA® Approval Conference Call
Omeros Corporation has announced a new date for its conference call to discuss the FDA approval of YARTEMLEA, the first therapy for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). The call is scheduled for January 7, 2026, to accommodate investor schedules. YARTEMLEA is set for U.S. market launch on January 2, 2026.
Read more →OMEROmeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros’ Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)
Omeros Corporation has finalized an asset purchase and licensing agreement with Novo Nordisk for its clinical-stage MASP-3 inhibitor, zaltenibart. The agreement includes an upfront payment of $240 million and potential total payments of up to $2.1 billion. Zaltenibart targets complement-mediated diseases and is positioned as a promising treatment option for various rare disorders. Omeros retains rights to its related small-molecule programs.
Read more →OMEROmeros Corporation Announces Pricing of $22 Million Registered Direct Offering SEATTLE, WA
Omeros Corporation announced a registered direct offering to sell approximately $22 million of its common stock at a price of $4.10 per share. This offering, priced at a 14% premium to its previous closing price, is set to close on or about July 28, 2025. The proceeds from this sale are expected to enhance the company's ability to develop its therapeutics targeting immunologic disorders and other health conditions. The offering follows a registration statement filed with the SEC, ensuring regulatory compliance.
Read more →OMEROmeros Corporation Reports Second Quarter 2023 Financial Results - Conference Call Today at 8:30 a.m. ET - SEATTLE, WA
Omeros Corporation announced its financial results for Q2 2023, showcasing continued efforts towards developing its therapeutics. The company is targeting a mid-2024 FDA decision for narsoplimab, which aims to be the first approved treatment for TA-TMA. Financial figures revealed an increased net loss and reduced royalties from OMIDRIA, though Omeros maintains a solid cash position to support ongoing projects. With several clinical trials underway, Omeros is optimistic about its future product developments and market opportunities.
Read more →OMEROmeros Corporation Reports First Quarter 2023 Financial Results - Conference Call Today at 4:30 p.m. ET - SEATTLE, WA
Omeros Corporation reported its financial results for Q1 2023, noting key advancements in clinical trials and ongoing regulatory discussions. The company continues to progress with its MASP-2 and MASP-3 inhibitors while benefiting from a $200 million milestone payment. Despite a slight increase in net loss compared to the previous year, the firm remains optimistic about its cash runway and upcoming developments. Notable revenues from royalty earnings declined, raising some concerns amid an evolving financial landscape.
Read more →OMEROmeros Corporation Reports Fourth Quarter and Year-End 2022 Financial Results - Conference Call Today at 4:30 p.m. ET - SEATTLE, WA
Omeros Corporation reported its fourth quarter and year-end 2022 financial results, indicating a net income of $128.7 million for the fourth quarter, primarily due to a milestone in discontinued operations. The company maintains robust financial flexibility with $400 million in resources to support operations and ongoing clinical trials, notably for narsoplimab. They are also engaging with the FDA for approval discussions and have shown promising developments in their various therapeutic programs, including those targeted at immunologic disorders and cancer. However, substantial losses from continuing operations raise concerns about financial sustainability.
Read more →OMERl Omeros Corporation Receives $200 Million Milestone Payment from Rayner Surgical - OMIDRIA -Related Payment Expected to Provide Operating Capital into at Least 2025 - SEATTLE, WA
Omeros Corporation announced a $200 million milestone payment from Rayner Surgical related to the sale of OMIDRIA. This payment, part of an Asset Purchase Agreement, boosts Omeros' capital available for operations, projected to last into at least 2025. Following this milestone, the royalty rate for U.S. sales of OMIDRIA has decreased but is still expected to generate significant revenue. Recent legislation secures ongoing separate payments for OMIDRIA, further supporting sales growth.
Read more →OMEROmeros Corporation Reports Third Quarter 2022 Financial Results - Conference Call Today at 4:30 p.m. ET - SEATTLE, WA
Omeros Corporation Reports Third Quarter 2022 Financial Results - Conference Call Today at 4:30 p.m. ET - SEATTLE, WA - November 9, 2022 - Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing smal
Read more →OMEROmeros Corporation Reports Second Quarter 2022 Financial Results - Conference Call Today at 4:30 p.m. ET - SEATTLE, WA
Omeros Corporation Reports Second Quarter 2022 Financial Results - Conference Call Today at 4:30 p.m. ET - SEATTLE, WA - August 9, 2022 - Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small
Read more →OMEROmeros Corporation Reports First Quarter 2022 Financial Results - Conference Call Today at 4:30 p.m. ET - SEATTLE, WA
Omeros Corporation Reports First Quarter 2022 Financial Results - Conference Call Today at 4:30 p.m. ET - SEATTLE, WA - May 10, 2022 - Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-mo
Read more →OMEROmeros Corporation Reports Fourth Quarter and Year-End 2021 Financial Results - Conference Call Today at 4:30 p.m. ET - SEATTLE, WA
Omeros Corporation Reports Fourth Quarter and Year-End 2021 Financial Results - Conference Call Today at 4:30 p.m. ET - SEATTLE, WA - March 1, 2022 - Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercia
Read more →OMEROmeros Completes Sale of OMIDRIA Franchise to Rayner Surgical SEATTLE
Omeros Completes Sale of OMIDRIA Franchise to Rayner Surgical SEATTLE - December 23, 2021 -- Omeros Corporation (Nasdaq: OMER) today announced that it has completed the sale of OMIDRIA (phenylephrine and ketorolac intraocular solution) 1.0%/0.3% to Rayner Surgical Group Inc., an
Read more →OMEROmeros Announces Agreement to Sell OMIDRIA Franchise to Rayner Surgical in a Transaction Valued in Excess of $1 Billion -- Transaction to Lock in Ongoing Revenue Stream for Omeros and Focus the Company on its Complement
Omeros Announces Agreement to Sell OMIDRIA Franchise to Rayner Surgical in a Transaction Valued in Excess of $1 Billion -- Transaction to Lock in Ongoing Revenue Stream for Omeros and Focus the Company on its Complement Franchise of MASP-2 and MASP-3 -- Conference call today
Read more →OMEROmeros Corporation Reports Third Quarter 2021 Financial Results - Conference Call Today at 4:30 p.m. ET - SEATTLE, WA
Omeros Corporation Reports Third Quarter 2021 Financial Results - Conference Call Today at 4:30 p.m. ET - SEATTLE, WA - November 9, 2021 - Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing sm
Read more →OMEROmeros Receives Complete Response Letter from FDA for Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA -- Conference call today at 8:30 a.m. ET, 5:30 a.m. PT -- SEATTLE
Omeros Receives Complete Response Letter from FDA for Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA -- Conference call today at 8:30 a.m. ET, 5:30 a.m. PT -- SEATTLE - October 18, 2021 -- Omeros Corporation (Nasdaq: OMER) today announced that the co
Read more →OMEROmeros Provides Regulatory Update on Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA SEATTLE
Omeros Provides Regulatory Update on Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA SEATTLE - October 1, 2021 -- Omeros Corporation (Nasdaq: OMER) today announced that the U.S. Food and Drug Administration (FDA) notified the company that, as part of
Read more →OMEROmeros Corporation Reports Second Quarter 2021 Financial Results - Conference Call Today at 4:30 p.m. ET - SEATTLE, WA
Omeros Corporation Reports Second Quarter 2021 Financial Results - Conference Call Today at 4:30 p.m. ET - SEATTLE, WA - August 9, 2021 - Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing sma
Read more →OMEROMEROS ANNOUNCES EXTENSION OF FDA REVIEW PERIOD FOR NARSOPLIMAB IN HSCT-TMA -- PDUFA Date is
OMEROS ANNOUNCES EXTENSION OF FDA REVIEW PERIOD FOR NARSOPLIMAB IN HSCT-TMA -- PDUFA Date is October 17, 2021 - SEATTLE - May 20, 2021 -- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing sm
Read more →OMEROmeros Corporation Reports First Quarter 2021 Financial Results - Conference Call Today at 4:30 p.m. ET - SEATTLE, WA
Omeros Corporation Reports First Quarter 2021 Financial Results - Conference Call Today at 4:30 p.m. ET - SEATTLE, WA - May 10, 2021 - Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-
Read more →OMEROmeros Corporation Reports Fourth Quarter and Year-End 2020 Financial Results - Conference Call Today at 4:30 p.m. ET - SEATTLE, WA
Omeros Corporation Reports Fourth Quarter and Year-End 2020 Financial Results - Conference Call Today at 4:30 p.m. ET - SEATTLE, WA - March 1, 2021 - Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commerc
Read more →OMEROmeros Corporation Reports Third Quarter 2020 Financial Results SEATTLE, WA
Omeros Corporation Reports Third Quarter 2020 Financial Results SEATTLE, WA - November 9, 2020 - Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for l
Read more →OMEROmeros Announces Pricing of Public Offerings --6,900,000 Shares of Common Stock-- --$210,000,000 of 5.25% Convertible Senior Notes due 2026-- SEATTLE--(BUSINESS WIRE)
Omeros Announces Pricing of Public Offerings --6,900,000 Shares of Common Stock-- --$210,000,000 of 5.25% Convertible Senior Notes due 2026-- SEATTLE--(BUSINESS WIRE)-August 12, 2020 -- Omeros Corporation (Nasdaq: OMER) ("Omeros") today announced that it has priced concurren
Read more →OMEROmeros Corporation Reports Second Quarter 2020 Financial Results SEATTLE, WA
Omeros Corporation Reports Second Quarter 2020 Financial Results SEATTLE, WA - August 10, 2020 - Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for l
Read more →OMEROmeros Corporation Reports First Quarter 2020 Financial Results – Conference Call Today at 4:30 p.m. ET – SEATTLE, WA –
Omeros Corporation Reports First Quarter 2020 Financial Results Conference Call Today at 4:30 p.m. ET SEATTLE, WA May 11, 2020 Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule
Read more →OMEROmeros Corporation Reports Fourth Quarter and Year-End 2019 Financial Results – Conference Call Today at 4:30 p.m. ET – SEATTLE, WA –
Omeros Corporation Reports Fourth Quarter and Year-End 2019 Financial Results Conference Call Today at 4:30 p.m. ET SEATTLE, WA March 2, 2020 Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing
Read more →OMERomer_Ex991 Omeros Corporation Appoints Former Amazon Treasurer Kurt Zumwalt to Board of Directors -- Zumwalt Also to Serve as Consultant, Bringing Extensive Capital Markets Background to Omeros -- SEATTLE, WA –
Omeros Corporation Appoints Former Amazon Treasurer Kurt Zumwalt to Board of Directors -- Zumwalt Also to Serve as Consultant, Bringing Extensive Capital Markets Background to Omeros -- SEATTLE, WA February 11, 2020 Omeros Corporation (NASDAQ: OMER) today announced the appointm
Read more →OMEROmeros Announces Pricing of Upsized Public Offering of Common Stock SEATTLE-(BUSINESS WIRE)
Omeros Announces Pricing of Upsized Public Offering of Common Stock SEATTLE-(BUSINESS WIRE)-December 5, 2019--Omeros Corporation (Nasdaq: OMER) ("Omeros"), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and
Read more →OMEROmeros Corporation Reports Third Quarter 2019 Financial Results – Conference Call Today at 4:30 p.m. ET – SEATTLE, WA –
Omeros Corporation Reports Third Quarter 2019 Financial Results Conference Call Today at 4:30 p.m. ET SEATTLE, WA November 12, 2019 Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-mol
Read more →OMEROmeros Corporation Reports Second Quarter 2019 Financial Results – Conference Call Today at 4:30 p.m. ET – SEATTLE, WA –
Omeros Corporation Reports Second Quarter 2019 Financial Results Conference Call Today at 4:30 p.m. ET SEATTLE, WA August 8, 2019 Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molec
Read more →OMEROmeros Corporation Reports First Quarter 2019 Financial Results - Conference Call Today at 4:30 p.m. ET - SEATTLE, WA
Omeros Corporation Reports First Quarter 2019 Financial Results - Conference Call Today at 4:30 p.m. ET - SEATTLE, WA - May 9, 2019 - Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-m
Read more →OMEROmeros Corporation Reports Fourth Quarter and Year-End 2018 Financial Results Conference Call Today at 8:30 a.m.
Omeros Corporation Reports Fourth Quarter and Year-End 2018 Conference Call Today at 8:30 a.m. ET SEATTLE, WA March 1, 2019 Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule a
Read more →OMEROmeros Corporation Appoints Thomas F. Bumol, Ph.D., to Board of Directors Former Lilly Biotechnology and Immunology Senior Vice President Drawn by Omeros Complement Franchise and Novel-Product Pipeline SEATTLE, WA
Omeros Corporation Appoints Thomas F. Bumol, Ph.D., to Board of Directors Former Lilly Biotechnology and Immunology Senior Vice President Drawn by Omeros Complement Franchise and Novel-Product Pipeline SEATTLE, WA February 12, 2019 Omeros Corporation (NASDAQ: OMER) today announ
Read more →OMEROmeros Corporation Announces Record High Quarterly Revenue Results for the Fourth Quarter 2018 Broadening OMIDRIA Coverage from Payers and Increasing Funding for OMS721 Commercial Preparations SEATTLE, WA
Omeros Corporation Announces Record High Quarterly Revenue Results for the Fourth Quarter 2018 Broadening OMIDRIA Coverage from Payers and Increasing Funding for OMS721 Commercial Preparations SEATTLE, WA January 14, 2019 Omeros Corporation (Nasdaq: OMER), today announced unaud
Read more →OMEROmeros Corporation Reports Third Quarter 2018 Financial Results Conference Call Friday November 9th at 8:30 a.m.
Omeros Corporation Reports Third Quarter 2018 Financial Results Conference Call Friday November 9th at 8:30 a.m. ET SEATTLE, WA November 8, 2018 Omeros Corporation (NASDAQ: OMER) today announced recent highlights and developments as well as financial results for the third quar
Read more →OMEROmeros Corporation Reports Second Quarter 2018 Financial Results - Conference Call Today at 4:30 p.m. ET - SEATTLE, WA
Omeros Corporation Reports Second Quarter 2018 Financial Results - Conference Call Today at 4:30 p.m. ET - SEATTLE, WA - August 9, 2018 - Omeros Corporation (NASDAQ: OMER) today announced recent highlights and developments as well as financial results for the second quarter end
Read more →OMEROmeros Announces Settlement of Infringement Suit Against ANDA Filer Lupin Lupin Confirms Validity of OMIDRIA Patents SEATTLE, WA
Omeros Announces Settlement of Infringement Suit Against ANDA Filer Lupin Lupin Confirms Validity of OMIDRIA Patents SEATTLE, WA May 24, 2018 Omeros Corporation (Nasdaq: OMER) today announced that it has entered into a settlement agreement with Lupin Ltd. and its subsidiary Lu
Read more →OMEROmeros Corporation Reports First Quarter 2018 Financial Results - Conference Call Today at 4:30 p.m. ET - SEATTLE, WA
Omeros Corporation Reports First Quarter 2018 Financial Results - Conference Call Today at 4:30 p.m. ET - SEATTLE, WA - May 10, 2018 - Omeros Corporation (NASDAQ: OMER) today announced recent highlights and developments as well as financial results for the first quarter ended M
Read more →OMEROmeros Corporation Reports Fourth Quarter and Year-End 2017 Financial Results - Conference Call Today at 4:30 p.m. ET - SEATTLE, WA
Omeros Corporation Reports Fourth Quarter and Year-End 2017 Financial Results - Conference Call Today at 4:30 p.m. ET - SEATTLE, WA - March 1, 2018 - Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commerc
Read more →OMEROmeros Corporation Reports Third Quarter 2017 Financial Results - Conference Call Today at 4:30 p.m. ET - SEATTLE, WA
Omeros Corporation Reports Third Quarter 2017 Financial Results - Conference Call Today at 4:30 p.m. ET - SEATTLE, WA - November 9, 2017 - Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing sm
Read more →OMEROmeros Announces Settlement of Infringement Suit Against ANDA Filer Par Par Confirms Validity of OMIDRIA Patents and Agrees Not to Market a Generic Version of OMIDRIA Until 2032 SEATTLE, WA
Omeros Announces Settlement of Infringement Suit Against ANDA Filer Par Par Confirms Validity of OMIDRIA Patents and Agrees Not to Market a Generic Version of OMIDRIA Until 2032 SEATTLE, WA October 5, 2017 Omeros Corporation (NASDAQ: OMER) today announced that it entered into
Read more →OMEROmeros Responds to Statnews.com Story SEATTLE, WA
Omeros Responds to Statnews.com Story SEATTLE, WA August 23, 2017 Omeros Corporation (NASDAQ: OMER) stated today that it continues to pursue legal action to hold responsible those behind a series of defamatory reports about the company posted online under the pseudonym Art Doyl
Read more →OMERE XHIBIT 99.1 Omeros Announces Pricing of Public Offering of Common Stock SEATTLE, WA
Omeros Announces Pricing of Public Offering of Common Stock SEATTLE, WA August 15, 2017 Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-mar
Read more →OMEROmeros Data Show Continued Improvement in Patients with IgA Nephropathy Treated with OMS721 - Sustained Proteinuria Reduction and GFR Improvement in up to One-Year Follow-up Data - SEATTLE, WA
Omeros Data Show Continued Improvement in Patients with IgA Nephropathy Sustained Proteinuria Reduction and GFR Improvement in up to One-Year Follow-up Data - SEATTLE, WA August 14, 2017 Omeros Corporation (NASDAQ: OMER) today announced additional follow-up data from patients
Read more →OMEROmeros Corporation Reports Second Quarter 2017 Financial Results - Conference Call Today at 4:30 p.m. ET - SEATTLE, WA
Omeros Corporation Reports Second Quarter 2017 Financial Results - Conference Call Today at 4:30 p.m. ET - SEATTLE, WA - August 8, 2017 - Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing sma
Read more →OMEROmeros Corporation Reports First Quarter 2017 Financial Results -- Conference Call Today at 4:30 p.m. ET -- SEATTLE, WA
Omeros Corporation Reports First Quarter 2017 Financial Results -- Conference Call Today at 4:30 p.m. ET -- SEATTLE, WA - May 10, 2017 - Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule a
Read more →OMEROmeros Corporation Reports Fourth Quarter and Year-End 2016 Financial Results -- Conference Call Today at 4:30 p.m. ET -- SEATTLE, WA
Omeros Corporation Reports Fourth Quarter and Year-End 2016 Financial Results -- Conference Call Today at 4:30 p.m. ET -- SEATTLE, WA - March 16, 2017 - Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both
Read more →OMEROmeros Corporation Reports Third Quarter 2016 Financial Results -- Conference Call Today at 4:30 p.m. ET -- SEATTLE, WA
Omeros Corporation Reports Third Quarter 2016 Financial Results -- Conference Call Today at 4:30 p.m. ET -- SEATTLE, WA - November 9, 2016 - Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecu
Read more →OMEROmeros Announces Pricing of Public Offering of Common Stock SEATTLE, WA
Omeros Announces Pricing of Public Offering of Common Stock SEATTLE, WA August 11, 2016 Omeros Corporation (NASDAQ: OMER) announced today the pricing of a $40 million underwritten public offering of its common stock at a price to the public of $11.50 per share, before deducting
Read more →OMEROmeros Corporation Reports Second Quarter 2016 Financial Results -- Conference Call Today at 4:30 p.m. ET -- SEATTLE, WA
Omeros Corporation Reports Second Quarter 2016 Financial Results -- Conference Call Today at 4:30 p.m. ET -- SEATTLE, WA - August 9, 2016 - Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecul
Read more →OMEROmeros Corporation Reports First Quarter 2016 Financial Results -- Conference Call Today at 9:00 a.m. ET -- SEATTLE, WA
Omeros Corporation Reports First Quarter 2016 Financial Results -- Conference Call Today at 9:00 a.m. ET -- SEATTLE, WA - May 10, 2016 - Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule a
Read more →OMEROmeros Corporation Reports Fourth Quarter and Year-End 2015 Financial Results -- Conference Call Tomorrow, March 8, at 9:00 a.m. ET -- SEATTLE, WA
Omeros Corporation Reports Fourth Quarter and Year-End 2015 Financial Results -- Conference Call Tomorrow, March 8, at 9:00 a.m. ET -- SEATTLE, WA -- March 7, 2016 -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commerc
Read more →OMERDisclosure of Omidria Post-Launch Study Findings to Occur at Hawaiian Eye and Retina Conference SEATTLE, WA
Disclosure of Omidria Post-Launch Study Findings to Occur at Hawaiian Eye and Retina Conference SEATTLE, WA January 15, 2016 Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therap
Read more →OMEROmeros Corporation Reports Third Quarter 2015 Financial Results -- Conference Call Today at 4:30 p.m. ET -- SEATTLE, WA
Omeros Corporation Reports Third Quarter 2015 Financial Results -- Conference Call Today at 4:30 p.m. ET -- SEATTLE, WA -- November 9, 2015 -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-mole
Read more →OMEROmeros Corporation Reports Second Quarter 2015 Financial Results -- Conference Call Today at 4:30 p.m. ET -- SEATTLE, WA
Omeros Corporation Reports Second Quarter 2015 Financial Results -- Conference Call Today at 4:30 p.m. ET -- SEATTLE, WA -- August 10, 2015 -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-mole
Read more →OMERRajiv Shah, M.D., Appointed to Omeros Board of Directors SEATTLE, WA
Rajiv Shah, M.D., Appointed to Omeros Board of Directors SEATTLE, WA June 17, 2015 Omeros Corporation (NASDAQ: OMER) today announced that Rajiv Shah, M.D., recent Administrator of the United States Agency for International Development (USAID), has been appointed to serve on the
Read more →OMEROmeros Announces Exclusive License Agreement for Omeros Arthroscopic Product OMS103 U.S. Sales to Begin This Year SEATTLE, WA
Omeros Announces Exclusive License Agreement for Omeros Arthroscopic Product OMS103 U.S. Sales to Begin This Year SEATTLE, WA June 16, 2015 Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule an
Read more →OMEROmidria Receives Positive Opinion from European Medicines Agency s Committee for Medicinal Products for Human Use Unanimous Recommendation to Grant European Marketing Authorization for Omidria Based on Benefit/Risk Profi
Omidria Receives Positive Opinion from European Medicines Agency s Committee for Medicinal Products for Human Use Unanimous Recommendation to Grant European Marketing Authorization for Omidria Based on Benefit/Risk Profile SEATTLE, WA May 22, 2015 Omeros Corporation (NASDAQ:
Read more →OMEROmeros Corporation Reports First Quarter 2015 Financial Results Omidria Now Widely Available in the U.S. Following Commercial Launch SEATTLE
Omeros Corporation Reports First Quarter 2015 Financial Results Omidria Now Widely Available in the U.S. Following Commercial Launch SEATTLE May 11, 2015 Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing bot
Read more →OMEROmeros Corporation Reports Fourth Quarter and Year-End 2014 Financial Results 4Q 2014 net loss of $20.7 million, or $0.61 per share SEATTLE, WA
Omeros Corporation Reports Fourth Quarter and Year-End 2014 Financial Results 4Q 2014 net loss of $20.7 million, or $0.61 per share SEATTLE, WA March 16, 2015 Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializin
Read more →OMEROmeros Prices $75 Million Public Offering of Common Stock and Pre-Funded Warrants SEATTLE, WA
Omeros Prices $75 Million Public Offering of Common Stock and Pre-Funded Warrants SEATTLE, WA--January 29, 2015--Omeros Corporation (NASDAQ: OMER) today announced that it has priced an underwritten public offering of 2,995,506 shares of its common stock at a per share price to
Read more →OMEROmeros Corporation Reports Third Quarter 2014 Financial Results Omidria U.S. Commercial Launch Planned for Early 2015 SEATTLE
Omeros Corporation Reports Third Quarter 2014 Financial Results Omidria U.S. Commercial Launch Planned for Early 2015 SEATTLE November 10, 2014 Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecul
Read more →OMEROmeros Corporation Reports Second Quarter 2014 Financial Results FDA Approval of Omidria Received on
Omeros Corporation Reports Second Quarter 2014 Financial Results FDA Approval of Omidria Received on May 30, 2014 Seattle, WA August 11, 2014 Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule
Read more →OMEROmeros Receives FDA Approval of Omidria for Use in Cataract and Other Intraocular Lens Replacement Procedures Omeros to Host Conference Call Today at 4:30 p.m.
Omeros Receives FDA Approval of Omidria for Use in Cataract and Other Intraocular Lens Replacement Procedures Omeros to Host Conference Call Today at 4:30 p.m. ET SEATTLE June 2, 2014 Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration
Read more →OMEROmeros Corporation Reports First Quarter 2014 Financial Results Secures Additional $50.4 Million in Cash in 1Q 2014 Seattle, WA
Omeros Corporation Reports First Quarter 2014 Financial Results Secures Additional $50.4 Million in Cash in 1Q 2014 Seattle, WA May 12, 2014 Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing s
Read more →OMEROmeros Prices $35.0 Million Public Offering of Common Stock SEATTLE
Omeros Prices $35.0 Million Public Offering of Common Stock SEATTLE, March 14, 2014 /PRNewswire/ Omeros Corporation (NASDAQ: OMER) today announced that it has priced an underwritten public offering of 3,043,479 shares of its common stock at a price to the public of $11.50 per s
Read more →OMEROmeros Corporation Reports Fourth Quarter and Year-End 2013 Financial Results 4Q 2013 net loss of $1.8 million, or $0.05 per share SEATTLE, WA
Omeros Corporation Reports Fourth Quarter and Year-End 2013 Financial Results 4Q 2013 net loss of $1.8 million, or $0.05 per share SEATTLE, WA March 13, 2014 Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and
Read more →OMEROmeros Corporation Reports Third Quarter 2013 Financial Results Obtains Additional $17.4 Million in Cash in 4Q 2013 SEATTLE, WA
Omeros Corporation Reports Third Quarter 2013 Financial Results Obtains Additional $17.4 Million in Cash in 4Q 2013 SEATTLE, WA November 7, 2013 Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializ
Read more →OMEROmeros Settles Insurance Litigation Omeros to Receive $12.5 Million SEATTLE
Omeros Settles Insurance Litigation Omeros to Receive $12.5 Million SEATTLE, October 3, 2013 Omeros Corporation (NASDAQ: OMER) announced today that it entered into a settlement agreement with its insurer, Carolina Casualty Insurance Company (CCIC), related to CCIC s defense of
Read more →OMEROmeros Submits OMS302 Marketing Authorization Application to European Medicines Agency - European Market Launch Planned for Second Half of 2014 - SEATTLE, WA
Omeros Submits OMS302 Marketing Authorization Application to European Medicines Agency - European Market Launch Planned for Second Half of 2014 - SEATTLE, WA September 10, 2013 Omeros Corporation today announced that it recently submitted a Marketing Authorization Application (
Read more →OMEROmeros Corporation Reports Second Quarter 2013 Financial Results Seattle, WA
Omeros Corporation Reports Second Quarter 2013 Financial Results Seattle, WA August 9, 2013 Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and
Read more →OMEROmeros Submits New Drug Application to U.S. FDA for OMS302 - Submission of European Marketing Authorization Application Planned for this Quarter - SEATTLE, WA
Omeros Submits New Drug Application to U.S. FDA for OMS302 - Submission of European Marketing Authorization Application Planned for this Quarter - SEATTLE, WA August 1, 2013 Omeros Corporation (NASDAQ: OMER) announced that the company recently submitted a New Drug Application
Read more →OMEROmeros Corporation Reports First Quarter 2013 Financial Results Seattle, WA
Omeros Corporation Reports First Quarter 2013 Financial Results Seattle, WA May 10, 2013 Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and di
Read more →OMEROmeros Announces $16.2 Million Registered Direct Offering of Common Stock Seattle, WA
Omeros Announces $16.2 Million Registered Direct Offering of Common Stock Seattle, WA May 9, 2013 Omeros Corporation (NASDAQ: OMER) today announced that it has agreed to sell 3,903,004 shares of its common stock at a price of $4.14 per share, a two percent premium over the clos
Read more →OMEROmeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results Seattle, WA
Omeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results Seattle, WA March 18, 2013 Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagu
Read more →OMEROmeros Announces Positive OMS302 Safety Data in Phase 3 Clinical Trial Market Launch Expected First Half of 2014 Seattle, WA
Omeros Announces Positive OMS302 Safety Data in Phase 3 Clinical Trial Market Launch Expected First Half of 2014 Seattle, WA January 22, 2013 Omeros Corporation (NASDAQ: OMER) today announced the successful completion of the 90-day safety database lock in the second of the Comp
Read more →OMEROmeros Reports OMS103HP Phase 3 Clinical Trial Results Second MeniscectomyPhase 3 Clinical Trial Enrollment Targeted for First Half of 2013 Company to Host Conference Call Today at 5:00 p.m. EST Seattle, WA
Omeros Reports OMS103HP Phase 3 Clinical Trial Results Second MeniscectomyPhase 3 Clinical Trial Enrollment Targeted for First Half of 2013 Company to Host Conference Call Today at 5:00 p.m. EST Seattle, WA December 27, 2012 Omeros Corporation (NASDAQ: OMER) today reported res
Read more →OMEROmeros Corporation Reports Third Quarter 2012 Financial Results Seattle, WA
Omeros Corporation Reports Third Quarter 2012 Financial Results Seattle, WA November 9, 2012 Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies an
Read more →OMERArnold C. Hanish Elected to Board of Directors of Omeros Seattle, WA
Arnold C. Hanish Elected to Board of Directors of Omeros Seattle, WA September 27, 2012 Omeros Corporation (NASDAQ: OMER) today announced that its Board of Directors has elected Arnold C. Hanish to serve on the Company s Board. Mr. Hanish has also been appointed to serve as Cha
Read more →OMEROmeros Corporation Reports Second Quarter 2012 Financial Results Seattle, WA
Omeros Corporation Reports Second Quarter 2012 Financial Results Seattle, WA August 7, 2012 Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and
Read more →OMEROmeros Prices $30 Million Public Offering of Common Stock Seattle, WA
Omeros Prices $30 Million Public Offering of Common Stock Seattle, WA June 27, 2012 Omeros Corporation (NASDAQ: OMER) today announced that it has priced an underwritten public offering of 2,926,830 shares of its common stock at a price to the public of $10.25 per share for gros
Read more →OMEROmeros Corporation Reports First Quarter 2012 Financial Results Seattle, WA
Omeros Corporation Reports First Quarter 2012 Financial Results Seattle, WA May 10, 2012 Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and di
Read more →OMEROmeros Corporation Reports Fourth Quarter and Year-End 2011 Financial Results Seattle, WA March 15, 201 2 Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing
Omeros Corporation Reports Fourth Quarter and Year-End 2011 Financial Results Seattle, WA March 15, 2012 Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagu
Read more →OMEROmeros Ophthalmology Product OMS302 Achieves Primary and Secondary Endpoints in Phase 3 Clinical Trial -- Company to Host Conference Call Today at 9:00 a.m. EDT -- Seattle, WA
Omeros Ophthalmology Product OMS302 Achieves Primary and Secondary Endpoints in Phase 3 Clinical Trial -- Company to Host Conference Call Today at 9:00 a.m. EDT -- March 13, 2012 Omeros Corporation (NASDAQ: OMER) today reported positive data from its Phase 3 clinical trial eva
Read more →OMERBioMed Realty Trust, Inc. Rick Howe Senior Director, Corporate Communications (858) 207-5859 CONTACT: Omeros Corporation Jennifer Cook Williams Cook Williams Communications, Inc. (360) 668-3701 BIOMED REALTY AND
BIOMED REALTY AND OMEROS SIGN NEW 64,500 SQUARE FOOT LEASE IN SEATTLE SAN DIEGO, Calif. February 1, 2012 BioMed Realty Trust, Inc. (NYSE: BMR) announced today the signing of a new 15-year lease with Omeros Corporation (NASDAQ: OMER) for BioMed s Waterfront Research Center prope
Read more →OMEROmeros Corporation Reports Third Quarter 2011 Financial Results Seattle, WA
Omeros Corporation Reports Third Quarter 2011 Financial Results Seattle, WA November 8, 2011 Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies an
Read more →OMEROmeros Corporation Reports Second Quarter 2011 Financial Results Seattle, WA
Omeros Corporation Reports Second Quarter 2011 Financial Results Seattle, WA August 9, 2011 Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and
Read more →OMEROmeros Corporation Reports First Quarter 2011 Financial Results Seattle, WA May 10 , 201 1 Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products
Omeros Corporation Reports First Quarter 2011 Financial Results Seattle, WA May 10, 2011 Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, coagulopathies and disorders of the
Read more →OMEROmeros Reports Outcome of Phase 3 Trials of OMS103HP Webcast Conference Call Scheduled for 5:30pm EDT Today Seattle, WA
Omeros Reports Outcome of Phase 3 Trials of OMS103HP Webcast Conference Call Scheduled for 5:30pm EDT Today Seattle, WA March 31, 2011 Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on in
Read more →OMEROmeros Corporation Reports Fourth Quarter and Year-End 2010 Financial Results Seattle, WA
Omeros Corporation Reports Fourth Quarter and Year-End 2010 Financial Results Seattle, WA March 15, 2011 Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disord
Read more →OMEROmeros Announces Expansion of Exclusive License to PDE7 Inhibitors from Daiichi Sankyo Promising Data for the Treatment of Addiction and Compulsive Disorders Seattle, Washington
Omeros Announces Expansion of Exclusive License to PDE7 Inhibitors from Daiichi Sankyo Promising Data for the Treatment of Addiction and Compulsive Disorders Seattle, Washington February 22, 2011 Omeros Corporation (NASDAQ: OMER) today announced that its exclusive license to p
Read more →OMEROmeros Announces Completion of Acquisition of Assay for GPCR Program Seattle, WA
Omeros Announces Completion of Acquisition of Assay for GPCR Program Seattle, WA November 23, 2010 Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the centr
Read more →OMEROmeros Corporation Reports Third Quarter 2010 Financial Results Seattle, WA
Omeros Corporation Reports Third Quarter 2010 Financial Results Seattle, WA November 4, 2010 Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central ner
Read more →OMEROmeros Receives $20 Million from Vulcan Capital and $5 Million Grant Award from Washington State s Life Sciences Discovery Fund to Advance its GPCR Program Company to Host Webcast Conference Call Today at 4 p.m. EDT Seat
Omeros Receives $20 Million from Vulcan Capital and $5 Million Grant Award from Washington State s Life Sciences Discovery Fund to Advance its GPCR Program Company to Host Webcast Conference Call Today at 4 p.m. EDT Seattle, WA October 25, 2010 Omeros Corporation (NASDAQ: OMER
Read more →OMEROMEROS REPORTS SECOND QUARTER 2010 FINANCIAL RESULTS Seattle, WA
OMEROS REPORTS SECOND QUARTER 2010 FINANCIAL RESULTS Seattle, WA August 10, 2010 Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system
Read more →OMEROMEROS SECURES $40
OMEROS SECURES $40 MILLION COMMITTED EQUITY FINANCING FACILITY SEATTLE, WASHINGTON July 29, 2010 Omeros Corporation (NASDAQ: OMER) today announced that it has secured a committed equity financing facility under which it may sell up to $40 million of its shares of common stock
Read more →OMEROMEROS REPORTS FIRST QUARTER 2010 FINANCIAL RESULTS Seattle, WA
OMEROS REPORTS FIRST QUARTER 2010 FINANCIAL RESULTS Seattle, WA May 12, 2010 Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, to
Read more →OMEROmeros Corporation Reports Fourth Quarter and Year-End 2009 Financial Results Company Also Announces Two Additions to Management Team Seattle, WA
Omeros Corporation Reports Fourth Quarter and Year-End 2009 Financial Results Company Also Announces Two Additions to Management Team Seattle, WA March 31, 2010 Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializ
Read more →OMEROmeros Licenses PDE7 Compounds for Parkinson s Disease Program Seattle, Washington
Omeros Licenses PDE7 Compounds for Parkinson s Disease Program Seattle, Washington March 9, 2010 Omeros Corporation (Nasdaq: OMER) today announced that it has obtained an exclusive license to compounds from Asubio Pharma Co., Ltd. for use in its PDE7 program, which is focused
Read more →OMERDaniel K. Spiegelman Elected to Board of Directors of Omeros Seattle, Washington
Daniel K. Spiegelman Elected to Board of Directors of Omeros Seattle, Washington December 09, 2009 Omeros Corporation today announced that its Board of Directors has elected Daniel K. Spiegelman to serve on the Company s Board. Mr. Spiegelman has also been appointed to serve a
Read more →OMEROmeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights Seattle, WA
Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights Seattle, WA November 19, 2009 Omeros Corporation (NASDAQ: OMER) today announced unaudited financial results for the third quarter ended September 30, 2009. For the three months ended Sep
Read more →Competitive Position
How OMER ranks across every disease it competes inCompetitive Position is a premium feature
See how OMER ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial